Can Cryotherapy Help with Inflammation and Arthritis? What the Evidence Shows (2026)

Chronic joint pain pushes a lot of people to look beyond their regular prescription pad, and cryotherapy has become one of the more visible non-drug options on offer in Irish clinics. It began as a sports recovery tool in the 1990s, marketed on the idea that a few minutes of extreme cold could calm the kind of inflammation that leaves muscles sore after a hard training session. That marketing has since expanded to cover arthritis as well, often with confident claims that a course of sessions will reduce joint inflammation generally.

The trouble with that broad claim is that arthritis is not one disease. Rheumatoid arthritis is an autoimmune condition in which the immune system attacks the joint lining, while osteoarthritis is a mechanical, wear-related condition affecting cartilage and the surrounding joint structures. A treatment that helps one does not automatically help the other, and treating the trial evidence for each as interchangeable is exactly the kind of shortcut that leads people astray.

This article looks at the two bodies of evidence separately and honestly: what has actually been tested in people with rheumatoid arthritis, and what has actually been tested in people with knee osteoarthritis, including a rigorous 2026 trial that reached a genuinely different conclusion from the older rheumatoid arthritis research.

The most commonly cited evidence for cryotherapy and arthritis is a 2013 systematic review published in Expert Review of Clinical Immunology, which searched PubMed, EMBASE, the Cochrane Library and LILACS for studies of local or whole-body cryotherapy in people with inflammatory rheumatic disease. After pooling six studies covering 257 people with rheumatoid arthritis who had not had recent joint surgery or infection, the reviewers found a significant reduction in pain, measured on a visual analogue scale, and in the 28-joint Disease Activity Score, a standard tool rheumatologists use to track how active a person's rheumatoid arthritis is, after repeated cryotherapy sessions used alongside standard treatment.

That is a real finding worth taking seriously, and it is why cryotherapy is sometimes discussed as an adjunct therapy for rheumatoid arthritis, potentially allowing lower doses of corticosteroids or anti-inflammatory drugs alongside it. But the reviewers were candid about the limits of what they had pooled. The six underlying studies were small, several used different cryotherapy protocols and equipment, and the review's own authors called explicitly for future randomised controlled trials with stronger methodology to confirm the effect. None of the six studies used a sham cryotherapy control, which matters more than it might sound, because a patient stepping into a cold chamber obviously knows they have received the active treatment.

In plain terms, this is a genuine, published signal from real patients with a real diagnosis, not a single study with an isolated result, but it rests on a decade-old pool of small trials that the reviewers themselves flagged as needing better-designed follow-up work.

The most rigorous recent test of cryotherapy for a specific arthritis diagnosis comes from a 2026 randomised controlled trial published in the Brazilian Journal of Physical Therapy, and it points in a different direction. Researchers at the Federal University of Sao Carlos recruited 120 adults aged 40 to 75 with knee pain and a radiographically confirmed diagnosis of grade 2 or 3 knee osteoarthritis, and randomly assigned them to one of three groups of 40: a structured exercise programme alone, the same exercise programme plus cryotherapy, or the same exercise programme plus a sham cryotherapy treatment designed to feel similar without the genuine cold exposure. Treatment ran three times a week for eight weeks, 24 sessions in total, with concealed allocation, blinded outcome assessors and an intention-to-treat analysis, the kind of design that gives a result real weight.

At the end of the eight weeks, there was no meaningful difference in pain at rest between any of the three groups, and the pattern held at follow-up. Exercise alone produced genuine improvement, consistent with exercise's established place as the first-line treatment for knee osteoarthritis, but adding cryotherapy on top of that exercise programme did not improve pain, physical function or quality of life any further than exercise plus a sham treatment did.

This is a null result, and a null result from a sham-controlled, blinded trial is not a disappointing footnote to skip past. It is, if anything, more informative than a positive result from a weaker design, because it directly tested whether cryotherapy adds anything once the obvious placebo response to receiving extra attention and an extra treatment is accounted for. For knee osteoarthritis specifically, the honest answer right now is that it does not appear to.

It would be easy to read the rheumatoid arthritis review and the 2026 osteoarthritis trial as conflicting evidence about the same question, but they are not really testing the same thing. Rheumatoid arthritis is driven by systemic immune activity, and the cryotherapy protocols used in the pooled RA studies were being tested as an adjunct to standard disease-modifying treatment in people with active inflammatory disease. Knee osteoarthritis, by contrast, is a localised, mechanical joint condition, and the 2026 trial tested cryotherapy specifically as an add-on to exercise, the treatment osteoarthritis guidelines already recommend as first-line care.

The quality of the two evidence bases also differs in an important way. The rheumatoid arthritis review pooled six generally small, non-sham-controlled studies, and its own authors asked for stronger trials to follow. The osteoarthritis trial is a single study, but it is a large, well-designed, sham-controlled trial with blinded assessors, exactly the design the earlier reviewers said was missing from their own field. A single strong trial does not settle a question forever, but it carries more weight than a pool of weaker ones, and it should not be dismissed just because an earlier, less rigorous body of evidence in a different disease reached a more encouraging conclusion.

Put simply, cryotherapy has a real, if dated and imperfectly tested, signal as an adjunct in rheumatoid arthritis, and a real, well-tested absence of added benefit in knee osteoarthritis specifically. Both of those things can be true at once.

The proposed mechanism behind cryotherapy's effect on joint inflammation centres on temperature. Lowering the temperature within and around a joint is thought to downregulate several of the chemical signals involved in joint inflammation and tissue damage, including pro-inflammatory cytokines, the enzymes that break down cartilage, and factors that promote the growth of new blood vessels feeding inflamed tissue. Reduced local blood flow during the cold exposure, followed by a rebound increase once the cold is removed, is also thought to influence how immune cells move through the affected area.

It is worth being clear about what kind of evidence this mechanistic picture rests on. Much of the detailed cellular work behind these ideas comes from laboratory and animal studies of joint tissue rather than from measurements taken in the human patients who took part in the rheumatoid arthritis or osteoarthritis trials described above. A plausible mechanism is a reasonable justification for testing a treatment in the first place, but it is not itself proof of a clinical benefit in a person with diagnosed arthritis, which is exactly why the two human trials above matter more than the mechanism alone.

Whole-body cryotherapy in Ireland typically costs between 50 and 100 euro for a single session, with clinics that sell blocks of five to ten sessions often bringing the per-session price down to somewhere around 40 to 60 euro. Localised cryotherapy, which targets a single joint with a directed cold-air device rather than exposing the whole body, is usually the cheaper option, often in the region of 30 to 60 euro per session, and it is the format most directly comparable to some of the localised protocols used in the rheumatoid arthritis studies described above.

Gerovia's directory currently lists eleven cryotherapy providers across Ireland and Northern Ireland, with clinics in Dublin, Cork, Galway, Belfast and Kilkenny among the areas covered, alongside smaller towns. Most operate as wellness or recovery services rather than medical clinics, so a session is generally booked directly rather than through a GP referral, though a responsible provider will still run a health screening before a first visit.

People considering cryotherapy specifically for an arthritis diagnosis should ask a prospective clinic what protocol they use, since the six rheumatoid arthritis studies pooled in the 2013 review used varying combinations of local and whole-body cryotherapy rather than one standard approach, and no single protocol has been established as most effective. Prices last checked September 2026 and vary between providers, so always confirm current pricing directly before booking.

Cryotherapy is not appropriate for everyone, arthritis or not. Standard contraindications used by reputable Irish clinics include uncontrolled high blood pressure and cardiovascular disease, Raynaud's phenomenon and other conditions involving abnormal sensitivity to cold, pregnancy, open wounds or active skin infections, uncontrolled epilepsy, and severe claustrophobia for whole-body chambers. People with rheumatoid arthritis, who may already be managing circulatory or cardiovascular complications associated with long-term inflammatory disease, should raise cryotherapy with their rheumatologist before starting, rather than assuming it is automatically safe because it is drug-free.

Cryotherapy should not be used as a substitute for disease-modifying treatment in rheumatoid arthritis or for the first-line exercise and weight-management approach recommended for knee osteoarthritis. The strongest reading of the evidence here treats it, at best, as a complementary addition alongside prescribed care, not a replacement for it, and anyone tempted to reduce or stop prescribed arthritis medication in favour of cryotherapy sessions should talk that decision through with their doctor first.

If you have rheumatoid arthritis, there is a genuine, if dated and methodologically limited, body of evidence suggesting cryotherapy used alongside standard treatment can reduce pain and disease activity, and it may be worth discussing with your rheumatologist as an adjunct, particularly if you are looking for ways to manage symptoms between flares. If you have knee osteoarthritis, the best current single trial, a large, sham-controlled, blinded study from 2026, found that cryotherapy added nothing beyond a structured exercise programme, which remains the treatment worth prioritising.

Either way, cryotherapy in Ireland is a low-risk, moderately priced option that sits outside the core medical system, and it is reasonable to try it as a complement to whatever your doctor has already recommended, provided you do not have a contraindication and you keep expectations calibrated to what the evidence, rather than the marketing, actually supports.